Senti Biosciences
- Founded: 2016
- Location: South SF, CA
- Employee range: 50 - 200
- Clinical stage: Clin0
- Therapy area: AML, MDS, other blood cancers
- Drug types: ONC, OPH, NEU, HEP
- Lead product: SENTI-202
- Product link: https://www.sentibio.com/pipeline
- Funding: $105M Jan 2021; $53M A Feb 2018
- Investors: Bayer
sentibio.com linkedin.com job board
Short description:
Gene Circuits; Cell & Gene Therapies
Drug notes:
SENTI-301A Clin0 hepatocellular carcinoma, solid tumors; SENTI-401 RD colorectal cancer, solid tumors; undisclosed programs RD solid tumors; 3 programs RD ocular, CNS & liver conditions; 3 programs RD regenerative medicine
Long description:
Senti Biosciences is outsmarting complex diseases by developing intelligent medicines using synthetic biology. Senti Bio designs and optimizes gene circuits, created from novel and proprietary combinations of DNA sequences, to reprogram cells. The gene circuits use biological logic to sense inputs, compute decisions and respond to their cellular environments. Senti Bio is using their Design-Build-Test-Learn development engine to make therapeutic gene circuits that can be engineered into product candidates. Senti Bio’s current focus is on advancing a broad pipeline of gene circuit-enabled products including CAR-NK cells for oncology, gene therapies for tissue-targets and cell therapies for regenerative medicines.
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com